CEVR
@tuftscevr.bsky.social
Center for the Evaluation of Value and Risk in Health at Medical Center. Posts and reposts are not endorsements.
https://cevr.tuftsmedicalcenter.org/
https://cevr.tuftsmedicalcenter.org/
Rapid genome sequencing performed early in a hospitalization can save ~$160k for critically ill infants with suspected genetic conditions- but most US insurers do not cover it.
Read more about this new Tufts Medical Center research: tinyurl.com/yc7mmxs7
Read more about this new Tufts Medical Center research: tinyurl.com/yc7mmxs7
Rapid Genome Sequencing Compared with a Gene Panel in Critically Ill Infants with a Suspected Genetic Disorder: An Economic Evaluation
To compare 1-year healthcare costs and quality-adjusted life years (QALYs) for two
diagnostic strategies in critically ill infants with suspected genetic disorders:
1) early rapid genome sequencing (w...
tinyurl.com
November 10, 2025 at 6:05 PM
Rapid genome sequencing performed early in a hospitalization can save ~$160k for critically ill infants with suspected genetic conditions- but most US insurers do not cover it.
Read more about this new Tufts Medical Center research: tinyurl.com/yc7mmxs7
Read more about this new Tufts Medical Center research: tinyurl.com/yc7mmxs7
Come see CEVR's faculty at ISPOR Europe 2025 in Glasgow, Scotland.
Details of our speaking engagements can be found at tinyurl.com/4em5ak2t
#ISPOREurope
Details of our speaking engagements can be found at tinyurl.com/4em5ak2t
#ISPOREurope
CEVR Participation at ISPOR EU 2025 - Center for the Evaluation of Value and Risk in Health
tinyurl.com
November 4, 2025 at 7:17 PM
Come see CEVR's faculty at ISPOR Europe 2025 in Glasgow, Scotland.
Details of our speaking engagements can be found at tinyurl.com/4em5ak2t
#ISPOREurope
Details of our speaking engagements can be found at tinyurl.com/4em5ak2t
#ISPOREurope
Join CEVR on Nov. 5 from 2:30-3:30 pm ET for a health policy seminar from Boshen Jiao, PhD, MPH. Dr. Jiao will discuss the inclusion of productivity, informal caregiving time, and future unrelated medical costs in economic evaluations.
More at: tinyurl.com/4ru3pmd8
More at: tinyurl.com/4ru3pmd8
CEVR Health Policy Seminar with Boshen Jiao, PhD, MPH - Center for the Evaluation of Value and Risk in Health
tinyurl.com
October 24, 2025 at 6:47 PM
Join CEVR on Nov. 5 from 2:30-3:30 pm ET for a health policy seminar from Boshen Jiao, PhD, MPH. Dr. Jiao will discuss the inclusion of productivity, informal caregiving time, and future unrelated medical costs in economic evaluations.
More at: tinyurl.com/4ru3pmd8
More at: tinyurl.com/4ru3pmd8
CEAs of SMA treatments frequently omit the effects of bereavement on caregivers, potentially undervaluing these interventions. Our new survey of bereaved parents better quantifies their experience of grief to inform future CEAs.
Read more at: tinyurl.com/2mcs6taa
Read more at: tinyurl.com/2mcs6taa
tinyurl.com
October 21, 2025 at 6:45 PM
CEAs of SMA treatments frequently omit the effects of bereavement on caregivers, potentially undervaluing these interventions. Our new survey of bereaved parents better quantifies their experience of grief to inform future CEAs.
Read more at: tinyurl.com/2mcs6taa
Read more at: tinyurl.com/2mcs6taa
The death of a child with SMA is a life-changing experience for parents, impacting their outlook on life, health, relationships, employment. New qualitative research explores the impacts of grief and strategies that help bereaved parents manage the loss of their child.
Read: tinyurl.com/mw2s2ezw
Read: tinyurl.com/mw2s2ezw
tinyurl.com
October 20, 2025 at 2:23 PM
The death of a child with SMA is a life-changing experience for parents, impacting their outlook on life, health, relationships, employment. New qualitative research explores the impacts of grief and strategies that help bereaved parents manage the loss of their child.
Read: tinyurl.com/mw2s2ezw
Read: tinyurl.com/mw2s2ezw
Going to AMCP 2025? Come see presentations by @mollytoba.bsky.social, Daniel Enright, and Angela Lin of CEVR's SPEC Team!
#AMCPNexus
#AMCPNexus
October 13, 2025 at 2:01 PM
Going to AMCP 2025? Come see presentations by @mollytoba.bsky.social, Daniel Enright, and Angela Lin of CEVR's SPEC Team!
#AMCPNexus
#AMCPNexus
US commercial payers vary in how they cover cell and gene therapies, according to a new study of 541 coverage policies by Tufts-CEVR’s SPEC team. 52% of policies had restrictions beyond FDA label, often limiting access to patient subgroups or requiring step therapy.
Read at: tinyurl.com/5dwhv726
Read at: tinyurl.com/5dwhv726
Variation in US Commercial Health Plan Coverage Restrictions for Cell and Gene Therapies
This Viewpoint examines variations in US commercial health plan coverage restrictions for cell and gene therapies.
tinyurl.com
September 30, 2025 at 7:16 PM
US commercial payers vary in how they cover cell and gene therapies, according to a new study of 541 coverage policies by Tufts-CEVR’s SPEC team. 52% of policies had restrictions beyond FDA label, often limiting access to patient subgroups or requiring step therapy.
Read at: tinyurl.com/5dwhv726
Read at: tinyurl.com/5dwhv726
CEAs often undervalue vaccines by excluding family spillover effects. New research from CEVR and Merck explores the impact of omissions.
Half of studied CEAs omitted spillover effects. Including them improved cost-eff. by avg. of ~20%; 10% of results became cost-saving.
Read: tinyurl.com/y8p6jtwm
Half of studied CEAs omitted spillover effects. Including them improved cost-eff. by avg. of ~20%; 10% of results became cost-saving.
Read: tinyurl.com/y8p6jtwm
tinyurl.com
September 22, 2025 at 5:46 PM
CEAs often undervalue vaccines by excluding family spillover effects. New research from CEVR and Merck explores the impact of omissions.
Half of studied CEAs omitted spillover effects. Including them improved cost-eff. by avg. of ~20%; 10% of results became cost-saving.
Read: tinyurl.com/y8p6jtwm
Half of studied CEAs omitted spillover effects. Including them improved cost-eff. by avg. of ~20%; 10% of results became cost-saving.
Read: tinyurl.com/y8p6jtwm
Older adults with dementia face substantial OOP costs. New CEVR research explores financial risks to patients/families: 21% of individuals w/ severe dementia face catastrophic costs; 12% fall below poverty threshold due to costs.
Read at: tinyurl.com/3pfbt7fp
@pattysynnott.bsky.social
Read at: tinyurl.com/3pfbt7fp
@pattysynnott.bsky.social
Characterizing financial risk from out‐of‐pocket expenditures across dementia stages
INTRODUCTION Older adults with dementia incur considerable out-of-pocket (OOP) health care expenses, but it is unclear how their financial burden differs by dementia stage. METHODS We identified 2...
tinyurl.com
September 17, 2025 at 5:02 PM
Older adults with dementia face substantial OOP costs. New CEVR research explores financial risks to patients/families: 21% of individuals w/ severe dementia face catastrophic costs; 12% fall below poverty threshold due to costs.
Read at: tinyurl.com/3pfbt7fp
@pattysynnott.bsky.social
Read at: tinyurl.com/3pfbt7fp
@pattysynnott.bsky.social
Join CEVR on Sept. 30 from 2-3 pm ET for a health policy seminar from Carl Asche, PhD, MSc. Dr. Asche will discuss new research to standardize definitions and outcomes reporting for patient-facing digital health interventions (PICOTS-ComTeC and CHEERS-DHI)
More at: tinyurl.com/ywn7abjp
More at: tinyurl.com/ywn7abjp
CEVR Health Policy Seminar with Carl Asche, PhD, MSc - Center for the Evaluation of Value and Risk in Health
cevr.tuftsmedicalcenter.org
September 3, 2025 at 7:26 PM
Join CEVR on Sept. 30 from 2-3 pm ET for a health policy seminar from Carl Asche, PhD, MSc. Dr. Asche will discuss new research to standardize definitions and outcomes reporting for patient-facing digital health interventions (PICOTS-ComTeC and CHEERS-DHI)
More at: tinyurl.com/ywn7abjp
More at: tinyurl.com/ywn7abjp
Join CEVR on Sept. 30 from 2-3 pm ET for a health policy seminar from Carl Asche, PhD, MSc. Dr. Asche will discuss his work to define patient-facing digital health interventions and standardize reporting practices (PICOTS-ComTeC and CHEERS-DHI)
More at: tinyurl.com/ywn7abjp
More at: tinyurl.com/ywn7abjp
CEVR Health Policy Seminar with Carl Asche, PhD, MSc - Center for the Evaluation of Value and Risk in Health
cevr.tuftsmedicalcenter.org
September 3, 2025 at 7:02 PM
Join CEVR on Sept. 30 from 2-3 pm ET for a health policy seminar from Carl Asche, PhD, MSc. Dr. Asche will discuss his work to define patient-facing digital health interventions and standardize reporting practices (PICOTS-ComTeC and CHEERS-DHI)
More at: tinyurl.com/ywn7abjp
More at: tinyurl.com/ywn7abjp
How can we make #valueassessment more patient-centric? New consensus recs from CEVR’s Tara Lavelle & colleagues include:
• Engage patients throughout
• Count all costs to patients & caregivers
• Share results in plain language
Read all 28 recommendations here: tinyurl.com/m9wxf6wj
• Engage patients throughout
• Count all costs to patients & caregivers
• Share results in plain language
Read all 28 recommendations here: tinyurl.com/m9wxf6wj
Achieving Patient-Centered Value/Health Technology Assessment: Recommendations From a Multistakeholder eDelphi Panel
Current methodological guidelines for value/health technology assessment (V/HTA) and
cost-effectiveness analysis describe traditional approaches not originally created
to be patient centered. The obje...
tinyurl.com
August 11, 2025 at 3:07 PM
How can we make #valueassessment more patient-centric? New consensus recs from CEVR’s Tara Lavelle & colleagues include:
• Engage patients throughout
• Count all costs to patients & caregivers
• Share results in plain language
Read all 28 recommendations here: tinyurl.com/m9wxf6wj
• Engage patients throughout
• Count all costs to patients & caregivers
• Share results in plain language
Read all 28 recommendations here: tinyurl.com/m9wxf6wj
New in Health Affairs: CMS should adopt a formal #HTA approach for #IRA drug price negotiations.
Benefits: transparency, broader evidence, more patients/stakeholder input, more acceptance of negotiations, etc.
More from @dano-hta.bsky.social et al: tinyurl.com/2s36yjta
@commonwealthfund.org
Benefits: transparency, broader evidence, more patients/stakeholder input, more acceptance of negotiations, etc.
More from @dano-hta.bsky.social et al: tinyurl.com/2s36yjta
@commonwealthfund.org
Health Technology Assessment, Again: A Transparent, Evidence-Based Approach For CMS Drug Price Negotiations | Health Affairs Journal
The Centers for Medicare and Medicaid Services (CMS) can now negotiate the prices of a set of drugs that represent significant Medicare expenditures. The long-term success of negotiations will depend ...
tinyurl.com
August 5, 2025 at 3:17 PM
New in Health Affairs: CMS should adopt a formal #HTA approach for #IRA drug price negotiations.
Benefits: transparency, broader evidence, more patients/stakeholder input, more acceptance of negotiations, etc.
More from @dano-hta.bsky.social et al: tinyurl.com/2s36yjta
@commonwealthfund.org
Benefits: transparency, broader evidence, more patients/stakeholder input, more acceptance of negotiations, etc.
More from @dano-hta.bsky.social et al: tinyurl.com/2s36yjta
@commonwealthfund.org
What explains the wide range of specialty drug rebates? New research from @mollytoba.bsky.social et al finds cancer/orphan drugs have the lowest rebates, and biosimilars/originators the highest.
Read more in Health Affairs Scholar at: tinyurl.com/y4rc468d
@argenx.com #PBM #Rebates #DrugPrices
Read more in Health Affairs Scholar at: tinyurl.com/y4rc468d
@argenx.com #PBM #Rebates #DrugPrices
What drug characteristics explain the wide range of manufacturer rebates?
AbstractIntroduction. Prescription drug list prices, often cited in policy discussions, do not account for rebates negotiated between manufacturers and pay
tinyurl.com
August 4, 2025 at 4:21 PM
What explains the wide range of specialty drug rebates? New research from @mollytoba.bsky.social et al finds cancer/orphan drugs have the lowest rebates, and biosimilars/originators the highest.
Read more in Health Affairs Scholar at: tinyurl.com/y4rc468d
@argenx.com #PBM #Rebates #DrugPrices
Read more in Health Affairs Scholar at: tinyurl.com/y4rc468d
@argenx.com #PBM #Rebates #DrugPrices
CEVR is thrilled to welcome David Strutton, PhD, as a Senior Fellow! Dr. Strutton brings 30+ years of global leadership in health policy, biopharma, and HTA. His expertise in real-world evidence and access strategy will be a tremendous asset.
Read more at: tinyurl.com/3bz9te3p
Read more at: tinyurl.com/3bz9te3p
David Strutton, PhD, to Join Tufts-CEVR as Senior Fellow - Center for the Evaluation of Value and Risk in Health
tinyurl.com
July 29, 2025 at 1:35 PM
CEVR is thrilled to welcome David Strutton, PhD, as a Senior Fellow! Dr. Strutton brings 30+ years of global leadership in health policy, biopharma, and HTA. His expertise in real-world evidence and access strategy will be a tremendous asset.
Read more at: tinyurl.com/3bz9te3p
Read more at: tinyurl.com/3bz9te3p
Meet Hao-Hsin (Taylor) Huang, MS, today’s featured #CEARegistry Summer Fellow. Taylor is pursuing her PhD in Pharmacy Systems, Outcomes, and Policy at the University of Illinois, Chicago.
Our thanks to the @moorefound.bsky.social for funding the CEA Registry Fellowship program!
Our thanks to the @moorefound.bsky.social for funding the CEA Registry Fellowship program!
July 28, 2025 at 2:42 PM
Meet Hao-Hsin (Taylor) Huang, MS, today’s featured #CEARegistry Summer Fellow. Taylor is pursuing her PhD in Pharmacy Systems, Outcomes, and Policy at the University of Illinois, Chicago.
Our thanks to the @moorefound.bsky.social for funding the CEA Registry Fellowship program!
Our thanks to the @moorefound.bsky.social for funding the CEA Registry Fellowship program!
Great application of our CEA Registry at the #Vanderbilt Center for Health Economic Modeling: 11 international fellows from #LMICs used the Registry to conduct CEAs of public health interventions.
Read more at: tinyurl.com/88varaue
@peterneumann11.bsky.social #ISPOR
Read more at: tinyurl.com/88varaue
@peterneumann11.bsky.social #ISPOR
VUMC researchers host international fellows for economic evaluation, decision science training
Vanderbilt recently hosted 11 international fellows to provide training to help them address public health issues in their home countries.
tinyurl.com
July 23, 2025 at 8:12 PM
Great application of our CEA Registry at the #Vanderbilt Center for Health Economic Modeling: 11 international fellows from #LMICs used the Registry to conduct CEAs of public health interventions.
Read more at: tinyurl.com/88varaue
@peterneumann11.bsky.social #ISPOR
Read more at: tinyurl.com/88varaue
@peterneumann11.bsky.social #ISPOR
New in JCER: CEVR’s Meng Li and @peterneumann11.bsky.social call for more value assessment of health services/procedures. These interventions are ~70% of health care spending but are often implemented without robust evidence and, unlike drugs, can cost more over time.
Read: tinyurl.com/ycxrppby
Read: tinyurl.com/ycxrppby
Value assessment for health services and procedures: a call to action in a new political climate
tinyurl.com
July 21, 2025 at 4:32 PM
New in JCER: CEVR’s Meng Li and @peterneumann11.bsky.social call for more value assessment of health services/procedures. These interventions are ~70% of health care spending but are often implemented without robust evidence and, unlike drugs, can cost more over time.
Read: tinyurl.com/ycxrppby
Read: tinyurl.com/ycxrppby
CEVR Summer Fellow Spotlight: we’re thrilled to have Rosemond Amamoo, MD, MPH as a #CEARegistry Summer Fellow! Rosemond is pursuing her PhD in Health and Pharmaceutical Outcomes at @uarizona.bsky.social.
Our thanks to the @moorefound.bsky.social for funding the CEA Registry Fellowship program!
Our thanks to the @moorefound.bsky.social for funding the CEA Registry Fellowship program!
July 21, 2025 at 3:57 PM
CEVR Summer Fellow Spotlight: we’re thrilled to have Rosemond Amamoo, MD, MPH as a #CEARegistry Summer Fellow! Rosemond is pursuing her PhD in Health and Pharmaceutical Outcomes at @uarizona.bsky.social.
Our thanks to the @moorefound.bsky.social for funding the CEA Registry Fellowship program!
Our thanks to the @moorefound.bsky.social for funding the CEA Registry Fellowship program!
Two weeks left to apply: Earn your #HEOR Certificate online from @tufts.edu with globally-recognized faculty like @peterneumann11.bsky.social, @dano-hta.bsky.social, James Chambers, and more from CEVR. Apply today!
Deadline is Aug. 1.
tinyurl.com/pr6drkhf
#RWE #pharma
Deadline is Aug. 1.
tinyurl.com/pr6drkhf
#RWE #pharma
Health Economics and Outcomes Research (HEOR) Certificate Program - Tufts CTSI
Overview The Tufts University Graduate School of Biomedical Sciences (GSBS) Clinical and Translational Science (CTS) Graduate Program is delighted to offer an accredited Certificate Program in Health ...
tinyurl.com
July 18, 2025 at 6:13 PM
Two weeks left to apply: Earn your #HEOR Certificate online from @tufts.edu with globally-recognized faculty like @peterneumann11.bsky.social, @dano-hta.bsky.social, James Chambers, and more from CEVR. Apply today!
Deadline is Aug. 1.
tinyurl.com/pr6drkhf
#RWE #pharma
Deadline is Aug. 1.
tinyurl.com/pr6drkhf
#RWE #pharma
Today’s #CEARegistry Summer Fellow is Pooja Gokhale, PharmD. Pooja is pursuing her PhD in Pharmaceutical Health Services, Outcomes, and Policy at @universityofga.bsky.social.
Our thanks to @moorefound.bsky.social for funding the CEA Registry Fellowship program!
Our thanks to @moorefound.bsky.social for funding the CEA Registry Fellowship program!
July 17, 2025 at 4:57 PM
Today’s #CEARegistry Summer Fellow is Pooja Gokhale, PharmD. Pooja is pursuing her PhD in Pharmaceutical Health Services, Outcomes, and Policy at @universityofga.bsky.social.
Our thanks to @moorefound.bsky.social for funding the CEA Registry Fellowship program!
Our thanks to @moorefound.bsky.social for funding the CEA Registry Fellowship program!
Larry Mose, MSc is today’s #CEARegistry Summer fellow. Larry earned his MSc from @york.ac.uk and hopes to work in the field of #HEOR.
Our thanks to the @moorefound.bsky.social for funding the CEA Registry Fellowship program!
Our thanks to the @moorefound.bsky.social for funding the CEA Registry Fellowship program!
July 14, 2025 at 5:13 PM
Larry Mose, MSc is today’s #CEARegistry Summer fellow. Larry earned his MSc from @york.ac.uk and hopes to work in the field of #HEOR.
Our thanks to the @moorefound.bsky.social for funding the CEA Registry Fellowship program!
Our thanks to the @moorefound.bsky.social for funding the CEA Registry Fellowship program!
1/ How closely do health plans’ drug #utilizationmanagement (UM) policies align with #clinicalguidelines? CEVR and NPC examined policies for 389 drug-indication pairs from 18 commercial insurers. Here’s a thread on what we found:
July 7, 2025 at 8:18 PM
1/ How closely do health plans’ drug #utilizationmanagement (UM) policies align with #clinicalguidelines? CEVR and NPC examined policies for 389 drug-indication pairs from 18 commercial insurers. Here’s a thread on what we found:
Reposted by CEVR
Strategic evidence planning in the IRA: Insights from Year 1 drug price negotiations | becarispublishing.com/digital-cont...
Strategic evidence planning in the IRA: Insights from Year 1 drug price negotiations | Becaris Publishing
becarispublishing.com
July 3, 2025 at 10:03 AM
Strategic evidence planning in the IRA: Insights from Year 1 drug price negotiations | becarispublishing.com/digital-cont...
Traditional #valueassessment lacks methods to evaluate #oncology combination txs, posing challenges for drugmakers, HTA bodies, and payers.
In a new commentary in Frontiers in Pharmacology, CEVR’s Dan Ollendorf et al explore available frameworks and chart a path forward: tinyurl.com/kh84ueb4
In a new commentary in Frontiers in Pharmacology, CEVR’s Dan Ollendorf et al explore available frameworks and chart a path forward: tinyurl.com/kh84ueb4
Frontiers | Value attribution for oncology combination regimens: going beyond frameworks to balance innovation, access, and affordability
Combination therapies are a mainstay in cancer treatment, but reimbursement access can be limited, owing to complexities around value assessment and pricing,...
tinyurl.com
July 2, 2025 at 2:45 PM
Traditional #valueassessment lacks methods to evaluate #oncology combination txs, posing challenges for drugmakers, HTA bodies, and payers.
In a new commentary in Frontiers in Pharmacology, CEVR’s Dan Ollendorf et al explore available frameworks and chart a path forward: tinyurl.com/kh84ueb4
In a new commentary in Frontiers in Pharmacology, CEVR’s Dan Ollendorf et al explore available frameworks and chart a path forward: tinyurl.com/kh84ueb4